Cited by 678Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer Genomics and Diagnostics

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas

Shigematsu, Hisayuki, Takahashi, Takao, Nomura, Masaharu, Majmudar, Kuntal, Suzuki, Makoto, Lee, Huei, Wistuba, Ignacio I., Fong, Kwun M., Toyooka, Shinichi, Shimizu, Nobuyoshi, Fujisawa, Takehiko, Minna, John D., Gazdar, Adi F.·2005·Cancer Research

DOI 10.1158/0008-5472.can-04-4235

Open this paper in CoChat — free account

Abstract

Mutations in the epidermal growth factor receptor gene (EGFR) in lung cancers predict for sensitivity to EGFR kinase inhibitors. HER2 (also known as NEU, EGFR2, or ERBB2) is a member of the EGFR family of receptor tyrosine kinases and plays important roles in the pathogenesis of certain human cancers, and mutations have recently been reported in lung cancers. We sequenced the tyrosine kinase domain of HER2 in 671 primary non-small cell lung cancers (NSCLC), 80 NSCLC cell lines, and 55 SCLCs and other neuroendocrine lung tumors as well as 85 other epithelial cancers (breast, bladder, prostate, and colorectal cancers) and compared the mutational status with clinicopathologic features and the presence of EGFR or KRAS mutations. HER2 mutations were present in 1.6% (11 of 671) of NSCLC and were absent in other types of cancers. Only one adenocarcinoma cell line (NCI-H1781) had a mutation. All HER2 mutations were in-frame insertions in exon 20 and target the identical corresponding region as did EGFR insertions. HER2 mutations were significantly more frequent in never smokers (3.2%, 8 of 248; P=0.02) and adenocarcinoma histology (2.8%, 11 of 394; P=0.003). In 394 adenocarcinoma cases, HER2 mutations preferentially targeted Oriental ethnicity (3.9%) compared with other ethnicities (0.7%), female gender (3.6%) compared with male gender (1.9%) and never smokers (4.1%) compared with smokers (1.4%). Mutations in EGFR, HER2, and KRAS genes were never present together in individual tumors and cell lines. The remarkable similarities of mutations in EGFR and HER2 genes involving tumor type and subtype, mutation type, gene location, and specific patient subpopulations targeted are unprecedented and suggest similar etiologic factors. EGFR, HER2, and KRAS mutations are mutually exclusive, suggesting different pathways to lung cancer in smokers and never smokers.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-04-4235

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237
Revisions in the International System for Staging Lung Cancer
Mountain, C. F. (1997) · CHEST Journal · doi:10.1378/chest.111.6.1710 · Cited by 4,565
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Self-citation

Show all 28 references

Sorted by citations

Items 601–678 of 678

Unveiling the Molecular Mechanisms Regulating the Activation of the ErbB Family Receptors at Atomic Resolution through Molecular Modeling and Simulations
Shih, A. (2011) · ScholarlyCommons (University of Pennsylvania)
Molecular Diagnosis of Lung Cancer
Chirieac, L. R., & Cagle, P. T. (2012) · Molecular pathology library · doi:10.1007/978-1-4614-3197-8_9
Epidermal Growth Factor Receptor Mutations and Sensitivity to Selective Kinase Inhibitors in Human Lung Cancer
Singh, A., Sharma, S. V., & Settleman, J. E. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-088-5_8
Les mutations de HER2 dans les cancers bronchiques : caractéristiques et perspectives thérapeutiques
Mazières, J., & Milia, J. (2012) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(12)70318-x
Expression of OLFM1 protein in lung cancer tissue and its significance
Wu, L., Yu, Y., Tan, X., CHANG, W.-J., Su, T., Cao, F., & Cao, G. (2010) · Academic Journal of Second Military Medical University · doi:10.3724/sp.j.1008.2010.00269
RET and Other Genes: Therapeutic Targets In Lung Adenocarcinoma
Kohno, T., Tsuchihara, K., Ogiwara, H., & Ichikawa, H. (2014) · Lung Cancer Management · doi:10.2217/lmt.13.77
Thérapies ciblées : comment déterminer la cible ?
Remmelink, M. (2014) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(14)70600-7
La génomique pour le cancer du poumon : qu’est-ce que chaque clinicien devrait savoir ?
Scherpereel, A. (2005) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(05)85667-0
Protein expression, gene amplification, epidermal growth factor receptor mutations and lung carcinoma
Panjković, M., Eri, Ž., Lovrenski, A., Ušaj, S. K., & Ivković-Kapicl, T. (2014) · Vojnosanitetski pregled · doi:10.2298/vsp121031016p
WITHDRAWN: Bronchial-pulmonary adenocarcinoma subtyping relates with different molecular pathways
de Sousa, V. M. L., Lopes-Bastos, B., Silva, M. J., Alarcão, A., & Carvalho, L. (2014) · Revista Portuguesa de Pneumologia · doi:10.1016/j.rppneu.2014.05.006
The Potential of Genome-Wide Analyses to Improve Non-Small-Cell Lung Cancer Care
Wright, C. M., Yang, I. A., Bowman, R., & Fong, K. M. (2014) · Lung Cancer Management · doi:10.2217/lmt.14.31
Self-citation
Cancer broncho-pulmonaire chez le non-fumeur
Planchard, D., & Soria, J. (2011) · Springer eBooks · doi:10.1007/978-2-287-99041-0_12
The 2013 Incentive Award of the Okayama Medical Association in General Medical Science (2013 Yuuki Prize)
Yamamoto, H. (2014) · Okayama Igakkai Zasshi (Journal of Okayama Medical Association) · doi:10.4044/joma.126.187
Role of ErbB2 and ErbB4 in Cancer Growth, Prognosis and as Targets for Immunotherapy
Hollmén, M. (2010) · UTUPub (University of Turku)
Genetic alterations and lineage specificity in lung cancer
Lockwood, W. W. (2009) · cIRcle (University of British Columbia) · doi:10.14288/1.0067516
HER
Köstler, W. J., & Yarden, Y. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139046947.011
17. Characteristics of Lung Cancer in Japanese Patients and Therapy
Nakanishi, Y. (2013) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.102.137b
Lung and Mediastinal Tumors
Chitale, D. A. (2015) · Springer eBooks · doi:10.1007/978-3-319-16304-8_8
Protein expression, gene amplification, epidermal growth factor receptor mutations and lung carcinoma Proteinska ekspresija, genska amplifikacija, mutacije receptora za faktor rasta epiderma i karcinom plua
Panjkovi, M., Lovrenski, A., Kne, S., & Ivkovi, T. (2014)
No Target Left Behind: Improving Therapeutic Options for ERBB2 -Mutant Non–Small Cell Lung Cancer
Redig, A. J., & Janne, P. A. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.009
17. Characteristics of Lung Cancer in Japanese Patients and Therapy
Nakanishi, Y. (2013) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.102.2468
SURGERY. THE GENE PROFILE OF NON-SMALL CELL LUNG CANCER AND THE INVASION OF MEDIASTINAL GANGLIA
Grigoroiu, M., Dima, S., Năstase, A., Bacalbașa, N., László, V., Klepetko, W., Popescu, I., & Régnard, J. (2014) · Journal of Translational Medicine and Research · doi:10.21614/jtmr-19-2-14
Signal Transduction Inhibitors of the HER Family
Brzezniak, C. E., Carter, C. A., Thomas, A., & Giaccone, G. (2013) · CRC Press eBooks · doi:10.1201/b15944-3
Tyrosine kinome profiling: oncogenic mutations and therapeutic targeting in cancer
Ghosh, P., Qiu, Y., Wang, L., & Kung, H. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139046947.009
her2 hyper-activation through the production of carboxy-terminal fragments
Angelini, P. D. (2014) · TDX (Tesis Doctorals en Xarxa)
Monoclonal Antibodies Targeting EGFR/HER2 and Clinical Outcomes in Cancer Treatment
Vermorken, J. B. (2013) · doi:10.2217/9781780843278
Lung Cancer Among Asian Americans
Park, S., Stram, D. O., Rouen, M. D., Gomez, S. L., Wu, A. H., & Cheng, I. C. (2016) · Springer eBooks · doi:10.1007/978-3-319-41118-7_5
Positive Mediators of Cell Proliferation in Neoplasia: Growth Factors and Receptors
Grumolato, L., & Aaronson, S. A. (2016) · Springer eBooks · doi:10.1007/978-1-59745-458-2_9 · Cited by 1
Development of Raman Spectroscopy as a Clinical Diagnostic Tool
Borel, S. (2016) · TSpace (University of Toronto)
Methods in Molecular Diagnosis
Hagiwara, K. (2017) · Springer eBooks · doi:10.1007/978-981-10-2002-5_4
Lung Adenocarcinoma
Mileham, K. F., Ersek, J. L., Kim, E. S., & Wistuba, I. I. (2017) · Wiley eBooks · doi:10.1002/9781119196235.ch19
Self-citation
Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2–Targeted Therapy
Chudnovsky, Y., Kumar, R. D., Schrock, A. B., Connelly, C. F., Gowen, K. A., Frampton, G. M., Erlich, R., Stephens, P. J., Miller, V. A., Ross, J. S., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00037
The many facets of lung adenocarcinoma – a disease comprising distinct molecular subgroups.
Gleinig, A., Huth, S., Dahmen, U., & Dirsch, O. (2015) · Medical Research Archives · doi:10.18103/mra.v1i6.411
Mutation Testing of Lung Cancer Biomarkers (Excluding IHC and NGS)
Portier, B. P. (2017) · Molecular pathology library · doi:10.1007/978-3-319-62941-4_7
Mutations as Predictive Biomarkers for Adenocarcinoma
Mahadevan, N. R., & Sholl, L. M. (2017) · Molecular pathology library · doi:10.1007/978-3-319-62941-4_11
Lung cancer and genitourinary cancers
Schrijvers, D. L. A. L. (2013) · doi:10.2217/ebo.13.211
Overview of pathophysiology and drug targets for non-small-cell lung cancer
Thomas, A., Rajan, A., & Giaccone, G. (2012) · doi:10.2217/ebo.11.404
Association between HER2 germline mutation A270S and prognosis in patients with primary breast cancer
Si, P., Xu, Y., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., Lin, B., & Xie, Y. (2018) · Cancer Biomarkers · doi:10.3233/cbm-170466
Le sevrage tabagique : éviter le cancer, réduire la toxicité des traitements et le risque de rechute
Ruppert, A.-M., Amrioui, F., Fallet, V., & Cadranel, J. L. (2018) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(18)30012-0
KRAS-Mutated Lung Cancer
Basu, A., & Nieva, J. J. (2019) · Current cancer research · doi:10.1007/978-3-030-17832-1_10
Avaliação de um novo candidato a fármaco para o tratamento do carcinoma de pulmão de células não pequenas
Kawamura, B. (2019) · doi:10.11606/d.5.2019.tde-10122019-120952
Identification of Novel Targets for Therapy in Solid Tumors
Hutchinson, K. E. (2015)
Le sevrage tabagique dans le cancer bronchique : les méthodes et les résultats ; place de la e-cigarette
Ruppert, A.-M., & Urban, T. (2020) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(20)30079-3
Drug Targets for Biologics
Lai, F., Hawkins, B. A., Cruz, E., Hanrahan, J. R., Groundwater, P. W., & Hibbs, D. E. (2020) · Wiley eBooks · doi:10.1002/9781119564690.ch5
Journal watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of clinical practice
McCullough, P. A., & Dieter, R. S. (2013) · Clinical Practice · doi:10.2217/cpr.13.80
Progress in anti-HER2 targeted therapy of metastatic lung cancer
Xiao, X. M., & Jia, Y. (2021) · E3S Web of Conferences · doi:10.1051/e3sconf/202127103074
Lung Carcinoma
Arcila, M. E., Chang, J. C., & Tafe, L. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-22922-1_6
Molecular Basis of Pulmonary Disease
Zander, D. S., & Farver, C. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802761-5.00018-3
Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of clinical practice
McCullough, P. A., Friedman, J. H., & Santos, E. S. (2013) · Clinical Practice · doi:10.2217/cpr.13.26
HER-2 mutations in lung cancer
Weerakkody, Y., Warner, R., & Bell, D. (2019) · Radiopaedia.org · doi:10.53347/rid-69172
HER2-Activating Missense Mutations in Advanced Non-Small Cell Lung Cancer: Rare But Targetable Spot Should Not Be NeglectedPreprint
Yang, G., Yang, Y., Liu, R., Hu, J., Xu, H., Li, W., Hao, X., & Wang, Y. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4155240
Understanding the Molecular Kinetics in NSCLC Through Computational Method
Nimsarkar, P., Gulhane, P., & Singh, S. (2022) · Springer eBooks · doi:10.1007/978-981-19-1953-4_7
Drug Resistance in Lung Cancer
Colarusso, C., Terlizzi, M., Pinto, A., & Sorrentino, R. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_62
Ex Vivo Drug Testing of Patient-Derived Lung Organoids to Predict Treatment Responses for Personalized MedicinePreprint
Hung, C., Williams, M., Williams, R., Chen, M., Kamali, S., Sambandam, V., Chiu, C. H.-L., Osmulski, P. A., Gaczynska, M. E., DeArmond, D. T., et al. (2023) · Preprints.org · doi:10.20944/preprints202306.1176.v1
Autres cibles addictives (KRAS, RET, HER2, NTRK…)
Planchard, D., Simon, É., Abdayem, P., & Greillier, L. (2023) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(23)00140-4
Genetic and Epigenetic Dysregulation in Environmental Disease
Ramos, K. S., Hassanin, A. A. I., & Wang, Y. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00034-4
Haramine-Mediated Anticancer Effects in Breast Cancer Cells: Targeting TAZ as a Therapeutic Strategy
Kumar, A., Vajidwal, A., Kumar, R., Maurya, A., & Pandey, V. (2024) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-19263
Thermodynamics and mechanism of afatinib–EGFR binding through a QM/MM approach
Kisku, A., Wahi, R., & Mishra, R. K. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00354g
Screening on Lung Cancer: Etiology, Pathophysiology, Treatment
Warkhade Kishor, K., & Pawar, R. D. (2025) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-29876
The Role of microRNAs in Bladder Urothelium Development and Tumorigenesis
Jia, A. Y. (2013) · doi:10.7916/d8qc09rx
Additional file 1 of Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature
Xu, H., Liang, Q., Xu, X., Tan, S., Wang, S., Liu, Y., & Liu, L. (2021) · Figshare · doi:10.6084/m9.figshare.17047311
Additional file 2 of Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature
Xu, H., Liang, Q., Xu, X., Tan, S., Wang, S., Liu, Y., & Liu, L. (2021) · Figshare · doi:10.6084/m9.figshare.17047314
Additional file 4 of Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature
Xu, H., Liang, Q., Xu, X., Tan, S., Wang, S., Liu, Y., & Liu, L. (2021) · Figshare · doi:10.6084/m9.figshare.17047320
Additional file 5 of Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature
Xu, H., Liang, Q., Xu, X., Tan, S., Wang, S., Liu, Y., & Liu, L. (2021) · Figshare · doi:10.6084/m9.figshare.17047323
Additional file 3 of Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature
Xu, H., Liang, Q., Xu, X., Tan, S., Wang, S., Liu, Y., & Liu, L. (2021) · Figshare · doi:10.6084/m9.figshare.17047317
An evolving landscape: predictive and therapeutic biomarkers in advanced non-small cell lung cancer
Fortman, D. D., & Qin, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1750153
Régulation de l'invasion cellulaire induite par les tyrosine kinases dans le cancer du sein
Chevalier, C. (2014) · theses.fr (ABES) · doi:10.70675/692c8de1za82az4e5ez953bz5e90670eb75d
Le cancer broncho-pulmonaire du non-fumeur : un modèle pour le diagnostic non-invasif des biomarqueurs tumoraux et l'évaluation de leurs interactions avec l'exposition aux facteurs de risque
Couraud, S. (2015) · theses.fr (ABES) · doi:10.70675/2a48d7b0zea07z442fz8e89z97aa7eabbe91
Contrôle de la progression tumorale broncho-pulmonaire par FHIT : Implication du récepteur HER2
Jouida, A. (2017) · theses.fr (ABES) · doi:10.70675/d7d69aafzfaebz4f24z855dz70ea0b9a846e
Évaluation du patrimoine tumoral circulant dans la prise en charge thérapeutique des patients atteints de cancer broncho-pulmonaire
Garcia, J. (2019) · theses.fr (ABES) · doi:10.70675/f648973az2136z4580z91b5z75a3710f1907
Compréhension des étapes précoces de la résistance adaptative aux inhibiteurs de tyrosine kinase de l'EGFR dans les cancers bronchiques
Figarol, S. (2020) · theses.fr (ABES) · doi:10.70675/9b097a88z7be2z4f00z913fze60d534fa601
Discrepancies in the Molecular Epidemiology of Druggable Genetic Alterations in Non-Small Cell Lung Cancer
Paliogiannis, P., Zinellu, A., Palmieri, G., & Fois, A. G. (2026) · Journal of Molecular Pathology · doi:10.3390/jmp7030031
Molecular characteristics and clinical outcomes of ERBB2-activating mutation-positive non-small cell lung cancer: A Japanese nationwide real-world cohort
Yamashita, M., Ninomiya, K., Tomida, S., Nakata, E., Morita, A., Hara, N., Takada, K., Makimoto, G., Kubo, T., Ichihara, E., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.117443
BindingDB Entry 5651: Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein.
BindingDB (2012) · UC San Diego · doi:10.7270/q27w69th
BindingDB Entry 50022481: BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.
BindingDB (2025) · UC San Diego · doi:10.7270/q2rb79br
Molecular Testing in Pulmonary Tumors
Tanguay, J., Karimi, S., Hwang, D. M., & Tsao, M. (2014) · Springer eBooks · doi:10.1007/978-1-4899-8050-2_13
Novel Role of ErbB-2 in Inhibition of Jagged-1-Mediated Trans-Activation of Notch in Breast Cancer
Pandya, K. (2013) · Loyola eCommons (Loyola University of Chicago)
Novel Therapeutic Strategies in Lung Cancer
Kurtyka, C. A. (2014) · Digital Commons - University of South Florida (University of South Florida)

Authors: Shigematsu, H., Takahashi, T., Nomura, M., Majmudar, K., Suzuki, M., Lee, H., Wistuba, I. I., Fong, K. M., Toyooka, S., Shimizu, N., Fujisawa, T., Minna, J. D., & Gazdar, A. F.
Affiliations: Okayama University (JP)
1Hamon Center for Therapeutic Oncology Research, Departments of
Chiba University (JP)
Chung Shan Medical University (TW)
The University of Texas MD Anderson Cancer Center (US)
Prince Charles Hospital (AU)
The University of Texas Southwestern Medical Center (US)
ORCID: Majmudar, Kuntal
Suzuki, Makoto
Wistuba, Ignacio I.
Fong, Kwun M.
Toyooka, Shinichi
Minna, John D.
Gazdar, Adi F.
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2005-03-01
Volume: 65
Issue: 5
Pages: 1642-1646
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-04-4235
OpenAlex: W2133867160
Cited by: 678
References: 28
Citations by year: 2026: 8 · 2025: 17 · 2024: 13 · 2023: 18 · 2022: 16 · 2021: 36 · 2020: 29 · 2019: 27 · 2018: 36 · 2017: 23 · 2016: 27 · 2015: 46 · 2014: 46 · 2013: 54 · 2012: 34
FWCI: 42.08
Type: journal article
Language: en
Open access: closed
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute ((P50-CA70907, P50CA070907, 5U01 CA 8497102)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: HER2 mutation, lung adenocarcinoma, non-small cell lung cancer, EGFR mutation, KRAS mutation, tyrosine kinase domain, never smokers, ethnic differences in mutation frequency, lung cancer etiology, EGFR kinase inhibitors
MeSH terms: Adenocarcinoma, Aged, Aged, 80 and over, Amino Acid Sequence, Female, Humans, Lung Neoplasms, Male, Middle Aged, Molecular Sequence Data, Mutation, Neoplasms, Glandular and Epithelial, Genes, ras, Sequence Homology, Amino Acid, Genes, erbB-2, Genes, erbB-1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks